Q: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Description: The Compound has the SMILES CC(C)c1cccc([C@H](C)C2CC2)c1O.
Answer: Phase 3 Clinical Trials
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
CC(C)c1cccc([C@H](C)C2CC2)c1O
CC(C)c1cccc([C@H](C)C2CC2)c1O
2-[(1R)-1-cyclopropylethyl]-6-propan-2-ylphenol
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.